Dermatological Drugs - D-A-CH

D-A-CH

In the year 2024, the projected revenue in the Dermatological Drugs market in the D-A-CH region is expected to reach US$0.96bn.
Looking ahead, it is anticipated that the market will experience an annual growth rate of 5.59% from 2024 to 2029, resulting in a market volume of US$1.26bn by 2029.
When compared globally, it is worth noting that United States is expected to generate the highest revenue in the Dermatological Drugs market, with a projected amount of US$11,670.00m in 2024.
Germany is experiencing a growing demand for dermatological drugs due to its aging population and high prevalence of skin disorders.

Key regions: United Kingdom, Canada, Japan, Europe, China

Market

Region

Region comparison

Currency

Analyst Opinion

The Dermatological Drugs market in D-A-CH is a growing market that is driven by several factors.

Customer preferences: Patients suffering from dermatological conditions such as acne, eczema, psoriasis, and rosacea have been increasing in D-A-CH. This has led to an increase in demand for dermatological drugs. Patients in D-A-CH are increasingly seeking treatment for their skin conditions, which has led to an increase in the number of prescriptions for dermatological drugs. Patients are also becoming more aware of the availability of new treatments and are willing to try them.

Trends in the market: The dermatological drugs market in D-A-CH is highly competitive, with several key players in the market. The market is expected to grow due to the increasing prevalence of skin diseases, the aging population, and the availability of new treatments. There has been an increasing trend towards the use of biologics in the treatment of dermatological conditions. Biologics are drugs made from living organisms and are used to treat a range of conditions, including psoriasis and eczema. They are often more effective than traditional drugs and have fewer side effects.

Local special circumstances: Germany is the largest market for dermatological drugs in D-A-CH. The German market is highly competitive, with several key players in the market. The market is expected to grow due to the increasing prevalence of skin diseases, the aging population, and the availability of new treatments. Switzerland has a smaller market for dermatological drugs but has a high per capita spending on healthcare. This has led to an increase in the availability of new treatments in the Swiss market. Austria has a smaller market for dermatological drugs but has a high per capita spending on pharmaceuticals.

Underlying macroeconomic factors: The dermatological drugs market in D-A-CH is influenced by several macroeconomic factors. The aging population is a key driver of the market, as older people are more likely to suffer from skin conditions. The availability of new treatments and the increasing prevalence of skin diseases are also important drivers of the market. The healthcare systems in D-A-CH are well-developed and provide access to a range of treatments. However, the high cost of some dermatological drugs can be a barrier to access for some patients. The market is also influenced by regulatory factors, such as the approval process for new drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.